Table 2.

Baseline characteristics, follow-up, and outcomes of 125 patients with NOS FSGS and 56 patients with collapsing FSGS according to exposure to immunotherapy with glucocorticoids and/or calcineurin inhibitors

CharacteristicsCollapsing, n=56NOS, n=125
ImmunotherapyNo ImmunotherapyP ValueImmunotherapyNo ImmunotherapyP Value
nnnn
Onset
 Age, yr3729 (19–46)1934 (26–42)0.638633 (16–52)3948 (23–67)<0.01
 Women, %3773.01952.60.158644.23943.6>0.99
 Black race, %3778.41978.90.258451.23540.00.32
 Hypertension, %3743.21936.80.756852.93554.31.00
 Serum creatinine, mg/dl371.4 (1.0–2.3)192 (1.5–3)0.03841.1 (0.8–1.6)381.6 (1.1–2.2)0.003
 eGFR by MDRD equation, ml/min per 1.73 m23654 (30–85)1735 (27–48)0.048366 (46–98)3845 (31–70)<0.001
 Up/c, g/g2010.5 (8.4–17.8)43.1 (2.0–5.9)<0.01517.6 (4.0–11.6)162.7 (1.9–5.5)0.002
 24-h Proteinuria, g/d2412.3 (6.5–14.7)1512.2 (4.4–15.0)0.92414.6 (2.7–12.0)263.1 (1.6–6.0)0.03
 Serum albumin, g/dl332.3 (1.9–2.9)192.4 (2.0–3.5)0.49742.2 (1.6–3.5)293.6 (3.3–4.0)<0.001
Follow-up
 Duration of follow-up, mo3774 (40–137)1936 (4–71)0.0038668 (24–136)3976 (21–164)0.89
 RAAS inhibition, %3781.11963.20.208695.33987.20.14
Outcomes
 Remission, %3070.0540.00.318165.43256.30.39
 ESRD,a %3735.11973.70.018625.63928.20.83
  • Continuous variables are expressed as medians (interquartile ranges). NOS, not otherwise specified; MDRD, Modification of Diet in Renal Disease, Up/c, urinary protein-to-creatinine ratio; RAAS, renin-angiotensin-aldosterone system.

  • a At last follow-up.